Research Advance of Immune Checkpoint Molecule TIGIT in Hematological Malignancies--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 993-997, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-880181
ABSTRACT
TIGIT is an inhibitory receptor containing T cell immunoglobulin and immune receptor protein tyrosine inhibitory motif domain. It shows high expression level on the surface of immune cells in tumor patients and plays an inhibitory role by binding to corresponding ligands, CD155 and CD112. Studying the mechanism of inhibitory effect of TIGIT and the way to block it shows a great significance in the immunotherapy of tumor. In this review, the structure of TIGIT molecule and its inhibitory effect on immune cells(including NK cells and T cells) were introduced, the expression level and the newest research advance of TIGIT molecule in lymphoma,multiple myeloma,leukemia and myelodysplastic syndrome were reviewed and summarized briefly, so as to provide reference for the further study of TIGIT and the application of TIGIT inhibitors in hematological malignancies.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Células Asesinas Naturales
/
Receptores Inmunológicos
/
Neoplasias Hematológicas
/
Proteínas de Punto de Control Inmunitario
/
Inmunoterapia
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS